Sign inJoin waitlistJoin the waitlist

CD

Christin DeStefano

Vice Chair of Clinical Research, Hematology/Oncology Division Director · National Capital Consortium

Credentials: · · · · ·

History

Hematology/Oncology Division Director · National Capital Consortium
Present
National Capital Consortium
Present

MedStar Georgetown University Hospital-Washington Hospital Center
2015–2018
Internal Medicine
Keesler Medical Center
2012–2015
Uniformed Services Univ of the Hlth Sci, F Edward Hebert Sch of Med
2008–2012
University of Georgia, B.S. Genetics
2004–2008

Research

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Journal for ImmunoTherapy of Cancer · 2022 · 78 citations
Management of post-transplant lymphoproliferative disorders
Review · British Journal of Haematology · 2018 · First of 4 authors · 70 citations
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Review · Blood and lymphatic cancer · 2022 · Last of 4 authors · Corresponding · 53 citations

CH
Christopher Hourigan
7 papers
SG
Steven Gibson
7 papers · 7 as a resident
Catherine Lai
5 papers
MR
Matthew Rendo
4 papers · 1 as a fellow
Aarthi Shenoy
3 papers
Dickran Kazandjian
3 papers
JC
Joseph Catlett
3 papers
JF
Joshua Fenderson
3 papers
AD
Alexander Dew
2 papers
HM
Helen Ma
2 papers
IS
Ian Stewart
2 papers
JC
John Cooper
2 papers

Clinical trials

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Principal investigator · Recruiting
Henry M. Jackson Foundation for the Advancement of Military Medicine
2025–2028
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2024–2030